Clinical Trials Directory

Trials / Terminated

TerminatedNCT00378495

Miltefosine for Brazilian Visceral Leishmaniasis

Status
Terminated
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
AB Foundation · Academic / Other
Sex
All
Age
2 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Miltefosine will be administered to Brazilian patients with kala azar

Detailed description

Miltefosine will be administered to Brazilian patients with kala azar. Both pediatric and adult patients will be studied. Patients will be followed for 6 months.

Conditions

Interventions

TypeNameDescription
DRUGMiltefosine: initially 2.5 mg/kg/day for 28 days

Timeline

Start date
2005-04-01
Primary completion
2007-04-01
Completion
2007-10-01
First posted
2006-09-20
Last updated
2016-07-12

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT00378495. Inclusion in this directory is not an endorsement.

Miltefosine for Brazilian Visceral Leishmaniasis (NCT00378495) · Clinical Trials Directory